24 February 2022

Biologics

Regulatory review – November 2021 PBAC recommendations

17 February 2022

Biologics osteomyelitis Spondyloarthritis

Rates and predictors of MTX side effects

17 February 2022

Biologics Pain Rheumatoid Arthritis

In knee OA, opioid benefits aren’t worth the cost

17 February 2022

Biologics PBS

Naloxone trial ‘saves three Australians a day’

17 February 2022

Biologics Pain

Long-term paracetamol may boost CV risk

3 February 2022

Biologics Comment Complementary Pain Research

The grass is always greener on the alternative side

27 January 2022

Biologics Polymyalgia Rheumatica

Stamp of reassurance for allopurinol in gout + CKD

9 December 2021

Biologics Pharmacy Guild of Australia

New treatments offer fresh hope for GCA patients

9 December 2021

Biologics Scleroderma

Promising findings for PsA treatments

9 December 2021

Biologics Clinical Software

Antibody trial finds reduction in Sjögren’s syndrome disease activity

9 December 2021

Biologics Comment Conditions

Read the November magazine online!

25 November 2021

Biologics Conditions

What else is your hypertensive patient taking?

25 November 2021

Biologics Comment COVID-19

Black Friday decision making, Covid and rituximab: is anyone buying?

18 November 2021

Biologics COVID-19

Cardiac toxicity risks with HCQ and CQ

18 November 2021

Biologics Conditions

Slow-release opioid therapy helps GPs treat illicit drug use

11 November 2021

Biologics Conditions Mental Health

Barbiturate scripts halve, but death rates spike